Compare CTSO & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | VNRX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.9M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | CTSO | VNRX |
|---|---|---|
| Price | $0.69 | $0.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $5.38 | $2.50 |
| AVG Volume (30 Days) | 124.8K | ★ 2.1M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,979,520.00 | $1,472,007.00 |
| Revenue This Year | $7.26 | $55.33 |
| Revenue Next Year | $9.78 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.89 | 14.48 |
| 52 Week Low | $0.60 | $0.23 |
| 52 Week High | $1.61 | $0.94 |
| Indicator | CTSO | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 34.54 |
| Support Level | $0.61 | $0.25 |
| Resistance Level | $0.77 | $0.27 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 53.86 | 17.77 |
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.